Cholangiocarcinoma Clinical Trials 2024: EMA, PDMA, FDA Approvals, Companies, Medication, Treatment Market, Therapies, ROA and MOA by DelveInsight

(Albany, USA) "Cholangiocarcinoma Pipeline Insight 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Cholangiocarcinoma Market.

The Cholangiocarcinoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Request for sample report @ Cholangiocarcinoma Pipeline Insight - https://www.delveinsight.com/sample-request/cholangiocarcinoma-cca-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key takeaways from the Cholangiocarcinoma Pipeline Report:
• Cholangiocarcinoma Companies across the globe are diligently working toward developing novel Cholangiocarcinoma treatment therapies with a considerable amount of success over the years.
• Cholangiocarcinoma companies working in the treatment market are Well Marker Bio, Sirnaomics, Kinnate Biopharma, Medivir, Eisai Co., Ltd., TransThera Biosciences, Hutchison Medipharma Limited, RedHill Biopharma Limited, Compass Therapeutics, Merck Sharp & Dohme, Eisai, Merck & Co, Zymeworks and BeiGene, Decalth Systems, Basilea Pharmaceutica, AstraZeneca, Taiho Oncology, and others, are developing therapies for the Cholangiocarcinoma treatment
• Emerging Cholangiocarcinoma therapies in the different phases of clinical trials are- WM-S1, STP-705, KIN-3248, MIV-818, E7090, TT-00420, HMPL-453, ABC294640, CTX-009, KEYTRUDA (pembrolizumab), Tasurgratinib (E7090), LENVIMA (lenvatinib), Zanidatamab, Melphalan, Derazantinib, Imfinzi (durvalumab), TAS-120 (futibatinib), and others are expected to have a significant impact on the Cholangiocarcinoma market in the coming years.
• In May 2023, Richard Kim discussed the investigation of RLY-4008 as a treatment for individuals diagnosed with cholangiocarcinoma possessing an FGFR2 fusion or rearrangement. RLY-4008, an exceptionally selective and irreversible FGFR2 inhibitor, is presently undergoing assessment in the phase 1/2 REFOCUS trial (NCT04526106). Initial data presented at the 2022 ESMO Congress revealed that among patients with FGFR inhibitor-naïve cholangiocarcinoma and an FGFR2 fusion or rearrangement (n = 17), there was an observed overall response rate of 88.2%.
• In April 2023, Nuvectis Pharma shared key findings from the poster presentation of NXP800 during the American Association for Cancer Research ("AACR") Annual Meeting 2023 held in Orlando, FL. The strong preclinical efficacy displayed by NXP800 in cholangiocarcinoma patient-derived xenograft (PDX) models is seen as a promising sign for potential clinical advantages. Cholangiocarcinoma is notably challenging to treat, often resulting in unfavorable outcomes, and these recent findings offer hope for future treatment prospects for patients.
• In April 2023, Verismo Therapeutics has been granted fast-track designation by the US Food and Drug Administration (FDA) for its investigational new drug, SynKIR-110. SynKIR-110 is an experimental medication aimed at addressing severe diseases and life-threatening conditions, specifically targeting mesothelin-expressing mesothelioma, ovarian cancer, and cholangiocarcinoma.
• In January 2023, Taiho Oncology, Inc. has announced the publication of findings from the pivotal Phase 2 FOENIX*-CCA2 clinical trial of futibatinib in The New England Journal of Medicine (NEJM) on January 19, 2023. The trial demonstrated substantial clinical benefits of futibatinib in patients previously treated for FGFR2 fusion/rearrangement-positive intrahepatic cholangiocarcinoma (iCCA). The results revealed an objective response rate of 42% upon independent review, with a median response duration of 9.7 months. Futibatinib exhibited enduring responses and survival rates that exceeded historical chemotherapy data for previously treated iCCA patients.
• In October 2022, Invitae has formed a collaboration with AstraZeneca, leveraging Invitae's Ciitizen natural history data for a comprehensive examination involving retrospective and prospective studies of individuals diagnosed with cholangiocarcinoma, a rare cancer affecting the bile duct. This partnership facilitates the exchange of meticulously curated, patient-consented data sourced from the Cholangiocarcinoma Foundation (CCF), a prominent patient advocacy group dedicated to discovering a cure and enhancing the lives of individuals impacted by cholangiocarcinoma.
• In November 2022, The FDA has awarded orphan drug designation for ZB131 in the treatment of cholangiocarcinoma, as confirmed by the drug's manufacturer. ZB131, developed by ZielBio, is a monoclonal antibody that demonstrates high affinity and specificity for cancer-specific plectin.

Cholangiocarcinoma Overview
Cholangiocarcinoma (CCA) is a rare and aggressive form of cancer that originates in the bile ducts, which are responsible for transporting bile from the liver to the small intestine. It is classified into three main types based on its location: intrahepatic (within the liver), perihilar (at the bile duct junction), and distal (near the small intestine). CCA often remains asymptomatic in its early stages, leading to late diagnoses and limited treatment options.
Common symptoms include jaundice, abdominal pain, weight loss, and fatigue. Risk factors for cholangiocarcinoma include chronic bile duct inflammation, primary sclerosing cholangitis, liver flukes, and certain genetic mutations. Diagnosis typically involves imaging techniques like MRI or CT scans, alongside blood tests and biopsy for histopathological confirmation.
Treatment depends on the stage and location of the cancer. Surgery offers the best chance for a cure if the tumor is localized, while advanced cases may require palliative care, chemotherapy, radiation, or targeted therapies. Emerging treatments like immunotherapy are being explored in clinical trials.
Despite its challenges, advancements in early detection and therapeutic strategies offer hope for improving outcomes in cholangiocarcinoma management. Early consultation with specialists is essential for timely intervention.

Get a Free Sample PDF Report to know more about Cholangiocarcinoma Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/cholangiocarcinoma-cca-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Emerging Cholangiocarcinoma Drugs Under Different Phases of Clinical Development Include:
• WM-S1: Well Marker Bio
• STP-705: Sirnaomics
• KIN-3248: Kinnate Biopharma
• MIV-818: Medivir
• E7090: Eisai Co., Ltd.
• TT-00420: TransThera Biosciences
• HMPL-453: Hutchison Medipharma Limited
• ABC294640: RedHill Biopharma Limited
• CTX-009: Compass Therapeutics
• KEYTRUDA (pembrolizumab): Merck Sharp & Dohme
• Tasurgratinib (E7090): Eisai
• LENVIMA (lenvatinib): Eisai and Merck & Co
• Zanidatamab: Zymeworks and BeiGene
• Melphalan: Decalth Systems
• Derazantinib: Basilea Pharmaceutica
• Imfinzi (durvalumab): AstraZeneca
• TAS-120 (futibatinib): Taiho Oncology

Cholangiocarcinoma Route of Administration
Cholangiocarcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.

Cholangiocarcinoma Molecule Type
Cholangiocarcinoma Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Cholangiocarcinoma Pipeline Therapeutics Assessment
• Cholangiocarcinoma Assessment by Product Type
• Cholangiocarcinoma By Stage and Product Type
• Cholangiocarcinoma Assessment by Route of Administration
• Cholangiocarcinoma By Stage and Route of Administration
• Cholangiocarcinoma Assessment by Molecule Type
• Cholangiocarcinoma by Stage and Molecule Type

DelveInsight's Cholangiocarcinoma Report covers around 60+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Cholangiocarcinoma product details are provided in the report. Download the Cholangiocarcinoma pipeline report to learn more about the emerging Cholangiocarcinoma therapies - https://www.delveinsight.com/sample-request/cholangiocarcinoma-cca-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key companies in the Cholangiocarcinoma Therapeutics Market include:
Key companies developing therapies for Cholangiocarcinoma are - Merck KGaA, Eisai Inc., Janssen Research & Development, LLC, 3D Medicines, Basilea Pharmaceutica, Hutchison Medipharma Limited, Jiangsu HengRui Medicine, TransThera Sciences, RedHill Biopharma, Eli Lilly and Company, Elevation oncology, Senhwa Biosciences, InnoCare Pharma, Genoscience Pharma, Intensity therapeutics, Elucida Oncology, GlaxoSmithKline, Verismo Therapeutics, Sirnaomics, Toray Industries, Inc, Kinnate Biopharma, Boehringer Ingelheim, Wellmarker Bio, Arbele Limited, NGM Biopharmaceuticals, Inc., Elicio Therapeutics, Xencor, Inc., Celon Pharma SA, and others.

Cholangiocarcinoma Pipeline Analysis:
The Cholangiocarcinoma pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Cholangiocarcinoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cholangiocarcinoma Treatment.
• Cholangiocarcinoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Cholangiocarcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cholangiocarcinoma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Cholangiocarcinoma drugs and therapies - https://www.delveinsight.com/sample-request/cholangiocarcinoma-cca-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Cholangiocarcinoma Pipeline Market Drivers
Increasing Incidence of Cholangiocarcinoma, increasing R&D Activities, increasing Awareness are some of the important factors that are fueling the Cholangiocarcinoma Market.

Cholangiocarcinoma Pipeline Market Barriers
However, high cost of drugs, high Incidence of adverse events and other factors are creating obstacles in the Cholangiocarcinoma Market growth.

Scope of Cholangiocarcinoma Pipeline Drug Insight
• Coverage: Global
• Key Cholangiocarcinoma Companies: Well Marker Bio, Sirnaomics, Kinnate Biopharma, Medivir, Eisai Co., Ltd., TransThera Biosciences, Hutchison Medipharma Limited, RedHill Biopharma Limited, Compass Therapeutics, Merck Sharp & Dohme, Eisai, Merck & Co, Zymeworks and BeiGene, Decalth Systems, Basilea Pharmaceutica, AstraZeneca, Taiho Oncology, and others
• Key Cholangiocarcinoma Therapies: WM-S1, STP-705, KIN-3248, MIV-818, E7090, TT-00420, HMPL-453, ABC294640, CTX-009, KEYTRUDA (pembrolizumab), Tasurgratinib (E7090), LENVIMA (lenvatinib), Zanidatamab, Melphalan, Derazantinib, Imfinzi (durvalumab), TAS-120 (futibatinib), and others
• Cholangiocarcinoma Therapeutic Assessment: Cholangiocarcinoma current marketed and Cholangiocarcinoma emerging therapies
• Cholangiocarcinoma Market Dynamics: Cholangiocarcinoma market drivers and Cholangiocarcinoma market barriers

Request for Sample PDF Report for Cholangiocarcinoma Pipeline Assessment and clinical trials - https://www.delveinsight.com/sample-request/cholangiocarcinoma-cca-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Cholangiocarcinoma Report Introduction
2. Cholangiocarcinoma Executive Summary
3. Cholangiocarcinoma Overview
4. Cholangiocarcinoma- Analytical Perspective In-depth Commercial Assessment
5. Cholangiocarcinoma Pipeline Therapeutics
6. Cholangiocarcinoma Late Stage Products (Phase II/III)
7. Cholangiocarcinoma Mid Stage Products (Phase II)
8. Cholangiocarcinoma Early Stage Products (Phase I)
9. Cholangiocarcinoma Preclinical Stage Products
10. Cholangiocarcinoma Therapeutics Assessment
11. Cholangiocarcinoma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Cholangiocarcinoma Key Companies
14. Cholangiocarcinoma Key Products
15. Cholangiocarcinoma Unmet Needs
16 . Cholangiocarcinoma Market Drivers and Barriers
17. Cholangiocarcinoma Future Perspectives and Conclusion
18. Cholangiocarcinoma Analyst Views
19. Appendix
20. About DelveInsight

Trending Reports:
• Bile Duct Neoplasm Market: https://www.delveinsight.com/report-store/bile-duct-cancer-market
• Biliary Tumor Market: https://www.delveinsight.com/report-store/biliary-tract-cancers-btcs-market
• Blood Gas And Electrolyte Analyzers Market: https://www.delveinsight.com/report-store/blood-gas-and-electrolyte-analyzers-market
• Brain Aneurysm Stents Market: https://www.delveinsight.com/report-store/intracranial-stents-market
• Car T Therapy For Acute Lymphoblastic Leukemia All Market: https://www.delveinsight.com/report-store/car-t-cell-therapy-for-acute-lymphoblastic-leukemia-market
• Cardiac Amyloidosis Market: https://www.delveinsight.com/report-store/al-amyloidosis-market
• Cardiac Restoration Systems Market: https://www.delveinsight.com/report-store/cardiac-restoration-systems-market
• Cervical Intraepithelial Neoplasia Market: https://www.delveinsight.com/report-store/cervical-cancer-market
• Chronic Cutaneous Ulcer Market: https://www.delveinsight.com/report-store/chronic-cutaneous-ulcer-market
• Chronic Rhinosinustis Market: https://www.delveinsight.com/report-store/chronic-rhinosinusitis-with-nasal-polyps-crswnp-market
• Concussions Market Size: https://www.delveinsight.com/report-store/concussions-market
• Continuous Renal Replacement Therapy Machines Market: https://www.delveinsight.com/report-store/continuous-renal-replacement-therapy-machines-market
• Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Duchenne Muscular Dystrophy Market: https://www.delveinsight.com/report-store/duchenne-muscular-dystrophy-market
• Emesis Market: https://www.delveinsight.com/report-store/emesis-market
• Exocrine Pancreatic Insufficiency Market: https://www.delveinsight.com/report-store/exocrine-pancreatic-insufficiency-epi-market
• Fuchs Dystrophy Market: https://www.delveinsight.com/report-store/fuchs-endothelial-corneal-dystrophy-fecd-market
• Gout Market: https://www.delveinsight.com/report-store/gout-market
• Gouty Arthritis Market: https://www.delveinsight.com/report-store/gout-market
• Head And Neck Squamous Cell Carcinoma Market: https://www.delveinsight.com/report-store/head-and-neck-cancer-hnc-market
• Healthcare Competitive Intelligence: https://www.delveinsight.com/blog/competitive-intelligence-in-healthcare-sector
• Hepatitis B Virus Market: https://www.delveinsight.com/report-store/chronic-hepatitis-b-virus-market
• Hpv-induced Cancers Market: https://www.delveinsight.com/report-store/human-papillomavirus-16-positive-hpv16-cancers-market
• Hyperuricemia Market: https://www.delveinsight.com/report-store/hyperuricemia-market
• Implantable Infusion Pumps Market: https://www.delveinsight.com/report-store/implantable-infusion-pumps-market
• Minimal Residual Disease Market: https://www.delveinsight.com/report-store/minimal-residual-disease-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/primary-research-services
Case study: https://www.delveinsight.com/case-study/esmo-conference-coverage

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.